WHO Alters Recommended COVID Treatments Amid Omicron Outbreak

Published on September 16, 2022

The World Health Organization has updated its guidance on COVID-19 treatments, advising against using the antibody drugs sotrovimab and casirivimab-imdevimab for patients. It’s like a weather forecaster updating their predictions—just when we thought we had the storm figured out, a new twist comes along. These drugs, previously conditionally recommended, are now off the table due to evolving knowledge of the Omicron variant. While we may feel discouraged, it’s important to remember that this is how science progresses! As researchers learn more about the virus and its variants, they update their recommendations to ensure the best treatment options. This change in guidelines suggests that other therapeutics may need to be explored or prioritized. Stay tuned for future updates as scientists continue to dive into the world of COVID-19 treatments.

In updated guidance issued Thursday, the World Health Organization now recommends against using the antibody drugs sotrovimab and casirivimab-imdevimab for patients with COVID-19. This recommendation replaces previous conditional recommendation for these antibody drugs. The…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>